The Grand-CHO Platform is the Boston Institute of Biotechnology’s groundbreaking innovation, revolutionizing biopharmaceutical production by integrating advanced cell line development, process optimization, and cutting-edge manufacturing technologies. This “Three-in-One” approach has positioned the Boston Institute of Biotechnology as a leader in cost-efficient, scalable biologics manufacturing.
Enhanced Cell Line Development
Central to the Grand-CHO Platform is the second-generation Epic-CHO cell line, which achieves exceptional productivity and stability. With expression levels reaching 10 g/L during the mini-pool stage and stability twice that of leading international cell lines, Epic-CHO sets a strong foundation for ultra-large-scale production. These advancements ensure reliability and efficiency across diverse manufacturing demands, meeting the growing global need for biologics.
Optimized Production Processes
The Grand-CHO Platform integrates high-density cell culture techniques with large-scale production processes, such as the 3,000L N-1 perfusion process and the 30,000L intensified Fed-batch production system. This combination reduces production cycle times by 30%, doubles yield per fermentation volume and minimizes restart times for large-scale projects from 60 days to just 30 days. By optimizing every stage of the production pipeline, the platform delivers unparalleled efficiency and scalability.
Unprecedented Cost Savings
A key driver of the Grand-CHO Platform is its ability to significantly reduce manufacturing costs. By enhancing cell line performance and streamlining production processes, the platform addresses one of the biopharmaceutical industry’s greatest challenges: balancing cost and quality. The resulting cost optimization has brought antibody drug production costs down to an industry-leading $10 per gram, making biologics more accessible to global markets.
Foundation for Pulse Continuous Manufacturing
The Grand-CHO Platform plays a pivotal role in enabling BIB’s innovative Pulse Continuous Manufacturing (PCM) model. By combining high-capacity upstream production with flexible downstream processing, PCM improves production efficiency by 50% to 300%. This integration exemplifies the platform’s versatility and its contribution to redefining industry standards for biologics manufacturing.
Future-Proofing Biopharmaceutical Production
The Grand-CHO Platform is more than a technological innovation—it represents a paradigm shift in biopharmaceutical production. With its emphasis on high performance, cost efficiency, and scalability, it empowers the Boston Institute of Biotechnology to address the growing demand for biologics while maintaining the highest standards of quality and reliability. By driving transformative change, the Grand-CHO Platform is shaping the future of biopharmaceutical manufacturing.
One Response
This platform offers a variety of interesting and practical information.
Visitors will discover content on different areas.
All materials are well-structured and easy to understand.
The site stays current with relevant information.
https://ziyicitu.com/2025/10/08/%E5%92%A9/
This makes it a trustworthy resource for everyday use.
When searching for quick answers or useful tips, the platform has something to offer.
The information comes in a accessible and convenient format.
As a result, this site remains valuable for a wide audience.